Amgen wins European approval to challenge argenx and UCB for autoimmune market
Belgian-Dutch biotech Argenx won European approval for its FcRn blocker Vyvgart in gMG in 2022 and secured authorization for a subcutaneous formulation of the therapy in 2023. The Commission approved UCB’s Rystiggo and J&J’s Imaavy in gMG in 2024 and …